Tentt

Merck to Acquire Terns Pharmaceuticals for $53/Share

Announced
HealthcareGoing Private

Deal Overview

Merck will acquire Terns Pharmaceuticals, Inc. through a tender offer by Thailand Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC. The offer is for all outstanding shares of Terns common stock.

The tender offer price is $53.00 per Share, net to the seller in cash, without interest, subject to applicable withholding taxes. The Schedule TO states the offer to purchase and letter of transmittal were dated April 7, 2026 and will be mailed to Terns stockholders along with a related Schedule 14D-9 filed by Terns.

Key Details

Transaction
Merck acquires Terns Pharmaceuticals
Deal Size
Over $100M
Reported Value
$53.00 per Share

Filed under

Source

Read full article on sec.gov

via SEC EDGAR — SC TO · April 7, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →